The B3GNT9 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from HeLa cervical adenocarcinoma cells. Disruption of the B3GNT9 gene eliminates endogenous beta-1,3-N-acetylglucosaminyltransferase activity, providing a loss-of-function model for studying glycosylation pathways. This polyclonal mixture contains a heterogeneous collection of edited alleles, offering a robust representation of the knockout phenotype in population-based assays without the need for clonal isolation.
HeLa is an immortalized epithelial cell line originating from a HPV18-positive cervical adenocarcinoma. Widely used as a model for aneuploidy and HPV-driven oncogenesis, HeLa cells express viral E6 and E7 oncoproteins that inactivate p53 and Rb, and they exhibit chromosomal instability. This background is particularly relevant for examining how glycosylation alterations influence cervical cancer progression and metastasis.
B3GNT9 encodes a beta-1,3-N-acetylglucosaminyltransferase that catalyzes the addition of GlcNAc to galactose in a beta-1,3 linkage, extending poly-N-acetyllactosamine (poly-LacNAc) chains on glycoproteins and glycolipids. Its transcription is regulated by SP1 and AP-1 and can be modulated by the Notch intracellular domain. The enzyme utilizes UDP-GlcNAc and functionally cooperates with B4GALT family galactosyltransferases and C1GALT1. Downstream, poly-LacNAc modifications on integrins, Notch receptors, EGFR, and cadherins critically influence receptor clustering, ligand binding, and adhesive strength. Consequently, B3GNT9 disruption reduces poly-LacNAc synthesis, impairing cell adhesion, migration, and signal transduction cascades.
In the HeLa background, loss of B3GNT9 function attenuates poly-LacNAc addition, leading to aberrant glycosylation of adhesion molecules and growth factor receptors. This creates a powerful model to dissect how defective glycosylation contributes to HPV-mediated oncogenic phenotypes such as enhanced migration, invasion, and drug resistance. The aneuploid nature of HeLa cells further mirrors the genomic instability characteristic of advanced cervical carcinomas, increasing the translational relevance.
Researchers can apply this knockout model to a broad spectrum of glycobiology and cancer research assays. Representative techniques include lectin blotting with L-PHA or E-PHA to detect poly-LacNAc levels, flow cytometry with anti-poly-LacNAc antibodies, glycoproteomic profiling, cell adhesion and wound-healing migration assays, and Western blotting for Notch or integrin glycosylation. The cells are also suitable for apoptosis and chemosensitivity studies. These applications position the product as a valuable tool for exploring glycosylation-dependent signaling, metastasis mechanisms, and HPV-mediated transformation. For detailed product information and technical support, please contact Ascent Research.
